Brief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
11/11/2026 06:12
BRIEF-Hansa Biopharma Q3 Rev Up At SEK 143 Mln Nov 11 (Reuters) - Hansa Biopharma AB HNSA.ST:
Q3 REVENUE TOTALS SEK 143.0 MILLION COMPARED TO SEK 30.8 MILLION IN Q3 2025
COMPLETES LICENSE AGREEMENT WITH SERB VALUED AT 115 MILLION EUROS
Source text: ID:nWkr5BgGWD
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS